As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Researchers couldn't be sure why the medicines, collectively known as GLP-1 agonists, may help in this way. But, experts ...

Even as real-world experiences indicate that microdosing or off-label use of GLP-1 drugs can offer benefits, physicians recommend caution around the dosage, timing, and mechanisms of action for now.

WEIGHT loss jabs slash alcohol cravings and can curb dangerous binge drinking, new research suggests.  The active drug ...

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... were likely driven by two main mechanisms of action -- the first being a reduction in ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...